Long - neue changes

NASDAQ:GMDA   Gamida Cell Ltd
SEC. gov

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Dr . Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Dr . Cohen-Dayag is President, Chief Executive Officer and a member of the board of directors of Compugen Ltd. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company’s computational discovery platforms. Prior to Compugen , Dr . Cohen-Dayag served as Head of R&D and was a member of the executive management team of Mindsense Biosystems Ltd. She also serves on the board of Pyxis Diagnostics, a private biotechnology company located in Jerusalem, Israel focused on developing a unique platform to identify predictive biomarkers in the field of immuno-oncology.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.